US Patent

US11058667 — Sacubitril-valsartan dosage regimen for treating heart failure

Method of Use · Assigned to Novartis AG · Expires 2036-05-09 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a specific dosage regimen for using the drug sacubitril-valsartan to treat heart failure in patients.

USPTO Abstract

The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3170`	—
`U-3170`	—
`U-3170`	—

Patent Metadata

Patent number: US11058667
Jurisdiction: US
Classification: Method of Use
Expires: 2036-05-09
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.